Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a Position Statement and new risk assessment tools from the Cardio ‐Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio‐Oncology Society
This article is protected by copyright. All rights reserved.
Source: European Journal of Heart Failure - Category: Cardiology Authors: Alexander R. Lyon,
Susan Dent,
Susanna Stanway,
Helena Earl,
Christine Brezden ‐Masley,
Alain Cohen‐Solal,
Carlo G. Tocchetti,
Javid Moslehi,
John D. Groarke,
Jutta Bergler‐Klein,
Vincent Khoo,
Li Ling Tan,
Markus S. Anker,
Stephan Haeh Tags: Position Paper Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Cardiology | Cardiovascular | Chemotherapy | Heart | Heart Failure | HER2 | Herceptin | Myeloma | Study | Toxicology